Applicant: Harris et al. Attorney's Docket No.: 1000141-00155 / 1412E

Serial No.: 10/717,217 RCE & Preliminary Amendment

Filed: November 18, 2003

AMENDMENTS TO THE CLAIMS:

Claims 5, 7, 8 and 11-22 and 42-44 are pending. Please add new claims 42-44. This listing of claims replaces all prior versions and listings of claims in the application.

LISTING OF CLAIMS:

- 1. 4. (Cancelled).
- 5. (Currently amended) A composition, comprising:

glycine; and

- a) an amino acid selected from the group consisting of a beta-alanine, an ester of a beta-alanine, and an amide of a beta-alanine, or
- b) a di-peptide selected from the group consisting of a beta-alanine di-peptide and a beta-alanylhistidine di-peptide.
- 6. (Cancelled).
- 7. (Currently amended) The composition of claim 5, wherein the beta-alanylhistidine dipeptide comprises is a carnosine, an anserine or a balenine.
- 8. (Previously presented) The composition of claim 5, further comprising at least creatine or a carbohydrate.

9 and 10. (Cancelled).

- 11. (Previously presented) The composition of claim 5, wherein the composition is a pharmaceutical composition.
- 12. (Previously presented) The composition of claim 5, wherein the composition is a dietary supplement or a sports drink.
- 13. (Previously presented) The composition of claim 12, wherein the dietary supplement or sports drink is a supplement for humans.
- 14. (Currently amended) A composition comprising at least 0.2, 0.3, 0.4, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 or 5 grams of a peptide or an ester comprising a beta-alanine per dosage.
- 15. (Currently amended) A composition comprising at least 0.2, 0.3, 0.4, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 grams of a peptide or an ester comprising a beta-alanine in an injectable form per dosage.
- 16. (Previously presented) The composition of claim 14 or claim 15, wherein the peptide comprises a beta-alanylhistidine dipeptide.

Applicant: Harris et al. Attorney's Docket No.: 1000141-00155 / 1412E RCE & Preliminary Amendment

Serial No.: 10/717,217

Filed : November 18, 2003

17. (Previously presented) The composition of claim 16, wherein the betaalanylhistidine dipeptide comprises a carnosine, an anserine or a balenine.

- 18. (Currently amended) A composition for humans comprising at least 200, 250, 300, 450, 500, 550, 600, 650, 700, 750 or 800 mg of a beta-alanine per dosage.
- 19. (Previously presented) The composition of claim 18, wherein the composition is formulated in an ingestible or an injectable formulation.
- 20. (Previously presented) The composition of claim 19, wherein the ingestible formulation is a drink, a gel, a food or a tablet.
- 21. (Previously presented) The composition of claim 18, wherein the peptide comprises a beta-alanylhistidine dipeptide.
- 22. (Previously presented) The composition of claim 20, wherein the betaalanylhistidine dipeptide comprises a carnosine, an anserine or a balenine.
 - 23. 41. (Cancelled).
- 42. (New) The composition of claim 5, wherein the composition is formulated for oral, enteral or parenteral administration.
- 43. (New) The composition of claim 5, wherein the composition is formulated for infusion through the skin of a subject.
- 44. (New) The composition of claim 43, wherein the composition is a topical cream or a patch.